AlphAIalphai — Financial news for AI agents
fiercepharma.comAUG 202 min read$AUPH

Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036

Aurinia Pharmaceuticals settled a patent dispute with Teva, delaying a generic version of Lupkynis until 2036. The deal assumes Teva's FDA approval and keeps Aurinia's market protection. Shares rose 7%. Aurinia faces ongoing litigation with other generics makers. Lupkynis is its only marketed drug, with H1 2024 revenue up 21% YoY.

Original reporting
fiercepharma.com
Published Aug 20, 2026, 3:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$AUPH
Bullish
high confidence
Mentioned
$AUPH
Relevance
7/10
alphai data visualization · based on fiercepharma.com
Decision brief

The 30-second read

$AUPHBullishHigh
01

Why it matters

The settlement removes immediate generic threat, likely sustaining current price momentum.

02

Market read

First‑report settlement news with material impact on Aurinia's valuation and sector dynamics.

03

What to watch

Pending litigation with other generics (DifGen, Dr. Reddy’s, etc.) could still erode market share.

Relevance 7/10Novelty 8/10Timing: same-day

Background

Aurinia's Lupkynis is its only marketed drug; protecting its patent life is critical for revenue.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

Aurinia settled with Teva, extending Lupkynis generic protection until Dec 2036, driving a 7% share rise.

Expected impact

Potential upside of 5‑10% over the next weeks as investors price in extended exclusivity.

Evidence & confidence

Extended patent protection is material for Aurinia's sole product, reducing dilution risk and improving revenue outlook.

Market effects

Sector

Strengthens the lupus therapeutic niche, may pressure peers GSK, Roche, AstraZeneca on pricing.

Regional

U.S. biotech sector gains confidence from reinforced IP enforcement.

Global

Limited to companies with similar biologic exclusivity concerns.

Counterpoint

What could challenge this read

If Teva secures FDA approval quickly, the settlement could be short‑lived, limiting upside.

Key entities

  • company
    Aurinia Pharmaceuticals

    U.S. biotech focused on lupus drug Lupkynis.

  • company
    Teva Pharmaceuticals

    Generic drug maker seeking to launch a voclosporin generic.

Read at source← All news

Related articles

AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min
AUG 19
$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

leaderpost.com2 min
AUG 19
$AUPHMed

Aurinia stock falls on Teva patent settlement for voclosporin

Aurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.

investing.com4 min
AUG 6
$AUPHMed

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.

thestarphoenix.com5 min